Aytu Biopharma IncNASDAQ:AYTU
- LAST PRICE3.2900
- TODAY'S CHANGE (%)0.0300 (0.9202%)
- Bid / Lots3.2800/ 9
- Ask / Lots3.3000/ 2
- Open / Previous Close3.3431 / 3.2600
- Day Range
- 52 Week Range
- Volume21,465
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AYTU |
|---|---|---|
| 09:44 ET | 100 | 3.3431 |
| 09:51 ET | 100 | 3.3029 |
| 09:57 ET | 792 | 3.3523 |
| 10:00 ET | 450 | 3.3589 |
| 10:02 ET | 100 | 3.2801 |
| 10:15 ET | 250 | 3.3381 |
| 10:24 ET | 650 | 3.29 |
| 10:27 ET | 400 | 3.3348 |
| 10:29 ET | 1400 | 3.3117 |
| 10:31 ET | 3400 | 3.31 |
| 10:33 ET | 150 | 3.29 |
| 10:36 ET | 800 | 3.3106 |
| 10:38 ET | 1300 | 3.3708 |
| 10:40 ET | 100 | 3.3452 |
| 10:47 ET | 100 | 3.33 |
| 10:49 ET | 100 | 3.3653 |
| 10:51 ET | 200 | 3.33 |
| 10:54 ET | 100 | 3.325 |
| 10:58 ET | 100 | 3.3386 |
| 11:03 ET | 100 | 3.3 |
| 11:05 ET | 489 | 3.3 |
| 11:07 ET | 1900 | 3.3 |
| 11:09 ET | 111 | 3.28 |
| 11:20 ET | 292 | 3.2819 |
| 11:27 ET | 250 | 3.28 |
| 11:30 ET | 400 | 3.305 |
| 11:41 ET | 670 | 3.3228 |
| 11:48 ET | 745 | 3.3 |
| 11:56 ET | 750 | 3.3075 |
| 11:57 ET | 805 | 3.3 |
| 11:59 ET | 250 | 3.3025 |
| 12:03 ET | 125 | 3.3051 |
| 12:10 ET | 1400 | 3.3 |
| 12:12 ET | 100 | 3.28 |
| 12:14 ET | 144 | 3.2886 |
| 12:32 ET | 400 | 3.29 |
| 12:35 ET | 130 | 3.29 |
Jan 25, 2023
Aytu BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement, from 10:38AM ET on Wednesday Jan 25, 2023 by MT Newswires
10:38AM ET on Wednesday Jan 25, 2023 by MT NewswiresBRIEF-Aytu Biopharma Regains Nasdaq Minimum Bid Price Compliance, from 8:10AM ET on Wednesday Jan 25, 2023 by Thomson Reuters
8:10AM ET on Wednesday Jan 25, 2023 by Thomson ReutersAytu BioPharma Regains Nasdaq Minimum Bid Price Compliance, from 8:01AM ET on Wednesday Jan 25, 2023 by Accesswire
8:01AM ET on Wednesday Jan 25, 2023 by Accesswire
Jan 24, 2023
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31, from 8:00AM ET on Tuesday Jan 24, 2023 by Accesswire
8:00AM ET on Tuesday Jan 24, 2023 by Accesswire
Jan 5, 2023
BRIEF-Aytu Biopharma Inc - On January 4, 2023, Board Approved A 1-For-20 Reverse Stock Split Of Company's Common Stock, Effective January 6, 2023, from 4:52PM ET on Thursday Jan 05, 2023 by Thomson Reuters
4:52PM ET on Thursday Jan 05, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aytu Biopharma Inc | 10.2M | -0.3x | --- |
Kali Inc | 1.0K | 0.0x | --- |
Interpharm Holdings Inc | 70.0 | 0.0x | --- |
Praxsyn Corp | 790.0 | 0.0x | --- |
China Medicine Corp | 78.0K | 0.0x | --- |
Journey Medical Corp | 26.1M | -0.8x | --- |
Company Information
Aytu BioPharma, Inc. is a pharmaceutical company. The Company is focused on commercializing therapeutics and consumer health products and developing therapeutics for rare pediatric-onset or difficult-to-treat diseases. It manufactures its products for the treatment of attention deficit hyperactivity disorder (ADHD) at its manufacturing facilities and uses third party manufacturers for its other prescription and consumer health products. The Company operates through two business segments: BioPharma and Consumer Health. The BioPharma segment consists of prescription pharmaceutical products (the Rx Portfolio). The Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company also has two product candidates in development, AR101 (enzastaurin) for the treatment of vascular Ehlers-Danlos Syndrome (VEDS) and Healight (endotracheal ultraviolet light catheter) for the treatment of severe, difficult-to-treat respiratory infections.
Contact Information
- Headquarters
- 373 Inverness Pkwy Ste 206ENGLEWOOD, CO, United States 80112-5898
- Phone
- 720-437-6580
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer
- Joshua Disbrow
- Chief Financial Officer
- Mark Oki
- Chief Operating Officer
- Christopher Brooke
- Independent Director
- Carl Dockery
- Independent Director
- John Donofrio
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.2M |
|---|---|
Revenue (TTM) | $102.4M |
Shares Outstanding | 3.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.42 |
EPS | $-12.13 |
Book Value | $1.19 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -83.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
